The respiratory disease specialist took its overall funding to $55m with a $41.4m round led by Novartis Venture Fund.
Novartis Venture Fund, the corporate venturing arm of pharmaceutical firm Novartis, led a 29m ($41.4m) series B round for UK-based respiratory disease therapy developer Enterprise Therapeutics yesterday.
Venture capital firm Versant Ventures co-led the round, which also featured a $3.5m investment by commercialisation firm IP Group and additional capital from VC firms Epidarex Capital and Forbion. IP Group’s commitment could rise to $6.6m dependent on milestones.
Founded in 2014, Enterprise Therapeutics is working on treatments for respiratory conditions caused by…